Research ArticleOriginal Article
Open Access

Emergence of Stenotrophomonas maltophilia nosocomial isolates in a Saudi children’s hospital

Risk factors and clinical characteristics

Jobran M. Alqahtani
Saudi Medical Journal May 2017, 38 (5) 521-527; DOI: https://doi.org/10.15537/smj.2017.5.16375

References

  1. ↵
    1. Looney WJ,
    2. Narita M,
    3. Muhlemann K
    (2009) Stenotrophomonas maltophilia : an emerging opportunist human pathogen. Lancet Infect Dis 9:312–323.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Brooke JS
    (2012) Stenotrophomonas maltophilia : An emerging global opportunistic pathogen. Clin Microbiol Rev 25:2–41.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Abbott IJ,
    2. Slavin MA,
    3. Turnidge JD,
    4. Thursky KA,
    5. Worth LJ
    (2011) Stenotrophomonas maltophilia : emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 9:471–488.
    OpenUrlCrossRefPubMed
    1. Garazi M,
    2. Singer C,
    3. Tai J,
    4. Ginocchio CC
    (2012) Bloodstream infections caused by Stenotrophomonas maltophilia : a seven-year review. J Hosp Infect 81:114–118.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Pien CJ,
    2. Kuo HY,
    3. Chang SW,
    4. Chen PR,
    5. Yeh HW,
    6. Liu CC,
    7. et al.
    (2015) Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. J Microbiol Immunol Infect 48:291–295.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Guyot A,
    2. Turton TF,
    3. Garner D
    (2013) Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 85:303–307.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Brooke JS
    (2014) New strategies against Stenotrophomonas maltophilia : a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12:1–4.
    OpenUrlCrossRefPubMed
  8. ↵
    1. del Toro MD,
    2. Rodriguez-Bano J,
    3. Herrero M,
    4. Rivero A,
    5. Garcia-Ordonez MA,
    6. Corzo J,
    7. et al.
    (2002) Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81:228–239.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Pakyz AL,
    2. Farr BM
    (2009) Rates of Stenotrophomonas maltophilia colonization and infection in relation to antibiotic cycling protocols. Epidemiol Infect 137:1679–1683.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Clinical and Laboratory Standards Institute (CLSI)
    (2016) Performance Standards for Antimicrobial Susceptibility Testing (M100S. CLSI, Wayne (PA)), 26th ed.
  11. ↵
    1. Samonis G,
    2. Karageorgopoulos DE,
    3. Maraki S,
    4. Levis P,
    5. Dimopoulou D,
    6. Spernovasilis NA,
    7. et al.
    (2012) Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. Plos One 7:e37375.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Guzoglu N,
    2. Demirkol FN,
    3. Aliefendioglu D
    (2015) Haemorrhagic pneumonia caused by Stenotrophomonas maltophilia in two newborns. J Infect Dev Ctries 9:533–535.
    OpenUrl
  13. ↵
    1. Xun M,
    2. Zhang Y,
    3. Li B,
    4. Wu M,
    5. Zong Y,
    6. Yin Y
    (2014) Clinical characteristics and risk factors of infections caused by Stenotrophomonas maltophilia in a hospital in northwest China. J Infect Dev Ctries 8:1000–1005.
    OpenUrl
  14. ↵
    1. Asaad AM,
    2. Al-Ayed MS,
    3. Qureshi MA
    (2013) Emergence of unusual nonfermenting gram-negative nosocomial pathogens in a Saudi hospital. Jpn J Infect Dis 66:507–511.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Arthur C,
    2. Tang X,
    3. Romero JR,
    4. Gossett JG,
    5. Harik N,
    6. Prodhan P
    (2015) Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience. Pediatr Cardiol 36:509–515.
    OpenUrl
  16. ↵
    1. Mutlu M,
    2. Yılmaz G,
    3. Aslan Y,
    4. Bayramoglu G
    (2011) Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates. J Microbiol Immunol Infect 44:467–472.
    OpenUrlPubMed
  17. ↵
    1. Sattler CA,
    2. Mason EO,
    3. Kaplan SL
    (2000) Non-respiratory Stenotrophomonas maltophilia infection at a children’s hospital. Clin Infect Dis 31:1321–1330.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Horan TC,
    2. Andrus M,
    3. Dudeck MA
    (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Mermel LA,
    2. Allon M,
    3. Bouza E,
    4. Craven DE,
    5. Flynn P,
    6. O’Grady NP,
    7. et al.
    (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. In Murray PR,
    2. Baron EJ,
    3. Jorgensen JH,
    4. Pfaller MA,
    5. Yolken RH
    (2003) Manual of Clinical Microbiology Handbook (ASM Press, Washington (DC)).
  21. ↵
    1. European Committee on Antimicrobial Susceptibility Testing
    Clinical Breakpoints, Available from URL: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf. [Accessed 2011 March 1].
  22. ↵
    1. Fihman V,
    2. Le Monnier A,
    3. Corvec S,
    4. Jaureguy F,
    5. Tankovic J,
    6. Jacquier H,
    7. et al.
    (2012) Stenotrophomonas maltophilia -the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect 64:391–398.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Falagas ME,
    2. Kastoris AC,
    3. Vouloumanou EK,
    4. Rafailidis PI,
    5. Kapaskelis AM,
    6. Dimopoulos G
    (2009) Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 4:1103–1109.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Boucher HW,
    2. Talbot GH,
    3. Bradley JS,
    4. Edwards JE,
    5. Gilbert D,
    6. et al.
    (2009) Bad bugs, no drugs: no ESKAPE!An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Xun M,
    2. Zhang Y,
    3. Li B,
    4. Wu M,
    5. Zong Y,
    6. Yin Y
    (2014) Clinical characteristics and risk factors of infections caused by Stenotrophomonas maltophilia in a hospital in northwest China. J Infect Dev Ctries 8:1000–1005.
    OpenUrl
  26. ↵
    1. Gales AC,
    2. Jones RN,
    3. Forward KR,
    4. Linares J,
    5. Sader HS,
    6. Verhoef J
    (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in severely ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32(Suppl2):104–113.
    OpenUrlCrossRef
  27. ↵
    1. Averbuch D,
    2. Cordonnier C,
    3. Livermore DM,
    4. Mikulska M,
    5. Orasch C,
    6. Viscoli C,
    7. et al.
    (2013) Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4 2011). Haematologica 98:1836–1847.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Springer C,
    2. Eyal F,
    3. Michel J
    (1982) Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. J Pediatr 100:647–650.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Cho SY,
    2. Kang CI,
    3. Kim J,
    4. Ha YE,
    5. Chung DR,
    6. Lee NY,
    7. et al.
    (2014) Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother 58:581–583.
    OpenUrlAbstract/FREE Full Text
    1. Juhasz E,
    2. Pongracz J,
    3. Ivan M,
    4. Kristof K
    (2015) Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care center in Hungary. Acta Microbiol Immunol Hung 62:295–305.
    OpenUrl
    1. Wei C,
    2. Ni W,
    3. Cai X,
    4. Zhao J,
    5. Cui J
    (2016) Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments. PloS One 11:e0152132.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Al-Jasser AM
    (2006) Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 5:23–25.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Sader HS,
    2. Farrell DJ,
    3. Flamm RK,
    4. Jones RN
    (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program 2009-2012. Int J Antimicrob Agents 43:328–334.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Wu H,
    2. Wang JT,
    3. Shiau YR,
    4. Wang HY,
    5. Lauderdale TL,
    6. Chang SC,
    7. et al.
    (2012) A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immuno Infect 45:120–126.
    OpenUrl
  35. ↵
    1. Wang YL,
    2. Scipione MR,
    3. Dubrovskaya Y,
    4. Papadopoulos J
    (2014) Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 58:176–182.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Sader HS,
    2. Castanheira M,
    3. Farrell DJ,
    4. Flamm RK,
    5. Mendes RE,
    6. Jones RN
    (2016) Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centers: results from SENTRY Antimicrobial Surveillance Program (2011-2014). Int J Antimicrob Agents 48:144–150.
    OpenUrlCrossRef
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section